GeoVax Launching Trials of HIV Vaccines
Posted on: Tuesday, 17 July 2007, 12:03 CDT
GeoVax said Tuesday it was launching two clinical trials of its potential HIV vaccines.
The trials were not scheduled to start until later this year, but GeoVax said it was launching them earlier due to positive results from previous studies.
The trials will involve the company's DNA and MVA vaccines that are intended to prevent infection with the HIV-1 strain of the virus. One trial will look at administering few vaccine doses, while the other trial will utilize only the MVA vaccine.
The excellent vaccine safety profile demonstrated (in previous trials) was key to accelerating the start date of these new human trials, said Don Hildebrand, GeoVax's chief executive officer, president and co-founder. Equally important are the positive immune responses observed in people receiving only 1/10th of a dose of our vaccines. This is very encouraging news.
Source: United Press International
Related Articles
- Vical Reaches Initial Enrollment Milestone in Phase 2 Trial of DNA Vaccine Against CMV
- Preclinical Trial Results of GeoVax's Vaccines Demonstrate Potential to Protect Against Development of AIDS
- NeuroVax Launches Trial of MS Vaccine
- China's Human Trial of AIDS Vaccine Proceeding Smoothly
- Vical Initiates Trial of DNA Vaccine
- Vical Opens Phase 2 Trial of DNA Vaccine Against CMV
- Cell Genesys Reports Positive Results From Phase 2 Trial of GVAX(R) Vaccine for Leukemia in Chronic Myelogenous Leukemia
- Cell Genesys Initiates Second Phase 3 Clinical Trial of GVAX(R) Vaccine for Prostate Cancer
- Cell Genesys Receives Special Protocol Assessment From FDA for Second Phase 3 Trial of GVAX(R) Vaccine for Prostate Cancer
- Cell Genesys Reports Additional Positive Data From Phase 2 Trial of GVAX(R) Vaccine for Leukemia
 |
 |
User Comments (0)
RSS Feeds